Core--Real-time quantitative PCR
Core--Real-time quantitative PCR
批准号:
7552030
负责人:
Dao Pan
金额:
$7.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Biological AssayCellsConditionCore FacilityDNA SequenceDevelopmentEquipment and SuppliesEvaluationFundingGene TransferGenesGenotypeLentivirus VectorLymphocyteMeasuresMedicineMessenger RNAMetabolic DiseasesMethodologyMethodsModelingMucopolysaccharidosis IIMucopolysaccharidosis Type VII mouseMusNorthern BlottingOligonucleotide PrimersPolymerase Chain ReactionPreparationPrionsProceduresProteinsPurposeReactionReagentResearchResearch PersonnelReverse Transcriptase Polymerase Chain ReactionRibonucleasesRunningSafetyServicesSpecimenStandards of Weights and MeasuresSystemTechnical ExpertiseTechniquesTechnologyTimeValidationViral Vectorabstractinganimal caredesigngene correctiongene delivery systemgene therapygene therapy clinical trialinnovationmouse modelnovel strategiesprogramsquality assurancetransgene expressionvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The purpose of the Real-time Quantitative PCR Core is to assist investigators in evaluating gene transfer efficiency and transgene expression in target cells for projects in the Gene Therapy for Metabolic Disorders program. As initially demonstrated by a gene therapy clinical trial ("Lymphocyte gene therapy for Hunter syndrome), this technique fills a very significant scientific need, to accurately quantitate the presence of a gene, and to measure its expression by reverse transcriptase-PCR (RT-PCR) with a high level of sensitivity and reproducability. This core
will assist investigators in designing assay systems (paired oligonucleotide primers and an internal TaqMan probe, Black Hole Quencher probe, or SYBR Green), as well as accomplish the actual assays of research specimens. The availability of a core facility accomplishing assays for common biologic systems (e.g., gene and gene products for OTC, MPS I, and MPS VII mouse models) eliminates redundancy and provides a greater level of quality assurance. The new, quantitative technology also provides sensitive methods for "safety assays" (e.g., for
lentiviral vector RCR) that are much faster, reliable and inexpensive in comparison to existing culture approaches. The technique also provides a method of quantitating gene products (RT-PCR) for which there are no existing assays, or for DNA sequences that do not yield a translational or transcriptional end product (as might be needed for transposon vectors).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing CNS drug delivery via epigenetic modulation
-
批准号:10679755
-
项目类别:
-
资助金额:$58.37万
-
财政年份:2023
-
负责人:Dao Pan
-
依托单位:
Manipulation of microRNA for CNS delivery: implication to treatment of neurological LSD
-
批准号:10201374
-
项目类别:
-
资助金额:$55.65万
-
财政年份:2020
-
负责人:Dao Pan
-
依托单位:
Gaucher disease:Treatment of neurodegenerative disease
-
批准号:8723918
-
项目类别:
-
资助金额:$41.03万
-
财政年份:2013
-
负责人:Dao Pan
-
依托单位:
Gaucher disease:Treatment of neurodegenerative disease
-
批准号:9290966
-
项目类别:
-
资助金额:$41.45万
-
财政年份:2013
-
负责人:Dao Pan
-
依托单位:
Gaucher disease:Treatment of neurodegenerative disease
-
批准号:9069618
-
项目类别:
-
资助金额:$41.45万
-
财政年份:2013
-
负责人:Dao Pan
-
依托单位:
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery
-
批准号:7567421
-
项目类别:
-
资助金额:$32.81万
-
财政年份:2008
-
负责人:Dao Pan
-
依托单位:
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery
-
批准号:7692967
-
项目类别:
-
资助金额:$32.81万
-
财政年份:2008
-
负责人:Dao Pan
-
依托单位:
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery
-
批准号:8130702
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2008
-
负责人:Dao Pan
-
依托单位:
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery
-
批准号:7913103
-
项目类别:
-
资助金额:$2.01万
-
财政年份:2008
-
负责人:Dao Pan
-
依托单位:
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery
-
批准号:8321014
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2008
-
负责人:Dao Pan
-
依托单位:
In Vivo BM Stem Cell Gene Transfer for MPS type I
-
批准号:6923451
-
项目类别:
-
资助金额:$18.63万
-
财政年份:2005
-
负责人:Dao Pan
-
依托单位:
In Vivo BM Stem Cell Gene Transfer for MPS type I
-
批准号:7039094
-
项目类别:
-
资助金额:$21.82万
-
财政年份:2005
-
负责人:Dao Pan
-
依托单位:
Core--Real-time quantitative PCR
-
批准号:6861200
-
项目类别:
-
资助金额:$6.46万
-
财政年份:2004
-
负责人:Dao Pan
-
依托单位:
Core--Real-time quantitative PCR facility
-
批准号:6442594
-
项目类别:
-
资助金额:$10.62万
-
财政年份:2001
-
负责人:Dao Pan
-
依托单位:
Core--Real-time quantitative PCR facility
-
批准号:6325547
-
项目类别:
-
资助金额:$10.62万
-
财政年份:1995
-
负责人:Dao Pan
-
依托单位:
Core--Real-time quantitative PCR
-
批准号:7342411
-
项目类别:
-
资助金额:$7.23万
-
财政年份:--
-
负责人:Dao Pan
-
依托单位:
Core--Real-time quantitative PCR
-
批准号:7062722
-
项目类别:
-
资助金额:$6.65万
-
财政年份:--
-
负责人:Dao Pan
-
依托单位:
Core--Real-time quantitative PCR
-
批准号:7177716
-
项目类别:
-
资助金额:$6.85万
-
财政年份:--
-
负责人:Dao Pan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:肖将尉
-
依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
-
批准号:82072862
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐云升
-
依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
-
批准号:82070825
-
项目类别:面上项目
-
资助金额:53.0万元
-
批准年份:2020
-
负责人:徐西振
-
依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
-
批准号:81903002
-
项目类别:青年科学基金项目
-
资助金额:20.5万元
-
批准年份:2019
-
负责人:王斐斐
-
依托单位:
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
-
批准号:81402419
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:杨翠霞
-
依托单位:
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
-
批准号:31272541
-
项目类别:面上项目
-
资助金额:82.0万元
-
批准年份:2012
-
负责人:王春凤
-
依托单位:
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
-
批准号:31271248
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:李伟
-
依托单位:
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
-
批准号:81160050
-
项目类别:地区科学基金项目
-
资助金额:49.0万元
-
批准年份:2011
-
负责人:邵立健
-
依托单位: